# Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease

> **NCT05258682** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Mucpharm Pty Ltd** · enrollment: 30 (estimated)

## Conditions studied

- COVID-19 Pneumonia
- COVID-19
- Ventilator Associated Pneumonia
- COVID-19 Acute Respiratory Distress Syndrome

## Interventions

- **DRUG:** Bromelains
- **DRUG:** Acetylcysteine

## Key facts

- **NCT ID:** NCT05258682
- **Lead sponsor:** Mucpharm Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-01
- **Primary completion:** 2022-09-30
- **Final completion:** 2022-10-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05258682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05258682, "Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05258682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*